公开(公告)号：US20240301022A1

公开(公告)日：2024-09-12

申请号：US18598878

申请日：2024-03-07

Applicant: Aston University

Inventor： Michael J. Tisdale ,  Steven T. Russell

IPC: C07K14/47 ,  A23L33/17 ,  A61K9/00 ,  A61K31/137 ,  A61K31/138 ,  A61K38/17 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06 ,  A61K47/60 ,  A61K47/61

CPC classification number: C07K14/473 ,  A23L33/17 ,  A61K9/0014 ,  A61K9/0043 ,  A61K9/0053 ,  A61K31/137 ,  A61K31/138 ,  A61K38/17 ,  A61K38/1709 ,  A61K38/1741 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06 ,  A61K47/60 ,  A61K47/61

Abstract: The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering Zn-α2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as β adrenergin receptor agonists, β adrenergin receptor antagonists, and/or glycemic control agents.

公开(公告)号：US20240000888A1

公开(公告)日：2024-01-04

申请号：US18449358

申请日：2023-08-14

Applicant: Aston University

Inventor： Michael J. Tisdale ,  Steven T. Russell

IPC: A61K38/17 ,  A61K31/135 ,  A61K31/195 ,  A61K45/06 ,  A61K31/138

CPC classification number: A61K38/1741 ,  A61K31/135 ,  A61K31/195 ,  A61K38/1709 ,  A61K45/06 ,  A61K31/138 ,  A61K2300/00

Abstract: The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-α2-glycoprotein or a functional fragment thereof, methods of decreasing plasma insulin levels, methods of increasing skeletal muscle mass, and methods of bringing about a weight reduction or reduction in obesity. Also provided are pharmaceutical compositions for use thereof

公开(公告)号：US20210315969A1

公开(公告)日：2021-10-14

申请号：US17354742

申请日：2021-06-22

Applicant: Aston University

Inventor： Michael J. Tisdale ,  Steven T. Russell

IPC: A61K38/17 ,  A61K31/135 ,  A61K31/195 ,  A61K45/06 ,  A61K31/138

Abstract: The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-α2-glycoprotein or a functional fragment thereof, methods of decreasing plasma insulin levels, methods of increasing skeletal muscle mass, and methods of bringing about a weight reduction or reduction in obesity, Also provided are pharmaceutical compositions for use thereof.

公开(公告)号：US20200330554A1

公开(公告)日：2020-10-22

申请号：US16919728

申请日：2020-07-02

Applicant: Aston University

Inventor： Michael J. Tisdale ,  Steven T. Russell

IPC: A61K38/17 ,  A61K31/135 ,  A61K31/195 ,  A61K45/06 ,  A61K31/138

Abstract: The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-α2-glycoprotein or a functional fragment thereof, methods of decreasing plasma insulin levels, methods of increasing skeletal muscle mass, and methods of bringing about a weight reduction or reduction in obesity. Also provided are pharmaceutical compositions for use thereof.

公开(公告)号：US20180339019A1

公开(公告)日：2018-11-29

申请号：US16058887

申请日：2018-08-08

Applicant: Aston University

Inventor： Michael J. Tisdale ,  Steven T. Russell

IPC: A61K38/17 ,  A61K31/138 ,  A61K31/195 ,  A61K45/06 ,  A61K31/135

Abstract: The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-α2-glycoprotein or a functional fragment thereof, methods of decreasing plasma insulin levels, methods of increasing skeletal muscle mass, and methods of bringing about a weight reduction or reduction in obesity. Also provided are pharmaceutical compositions for use thereof.